Harnessing the therapeutic potential of the stem cell secretome in neonatal diseases.
Semin Perinatol
; 47(3): 151730, 2023 04.
Article
em En
| MEDLINE
| ID: mdl-36990921
ABSTRACT
Preterm birth and intrapartum related complications account for a substantial amount of mortality and morbidity in the neonatal period despite significant advancements in neonatal-perinatal care. Currently, there is a noticeable lack of curative or preventative therapies available for any of the most common complications of prematurity including bronchopulmonary dysplasia, necrotizing enterocolitis, intraventricular hemorrhage, periventricular leukomalacia and retinopathy of prematurity or hypoxic-ischemic encephalopathy, the main cause of perinatal brain injury in term infants. Mesenchymal stem/stromal cell-derived therapy has been an active area of investigation for the past decade and has demonstrated encouraging results in multiple experimental models of neonatal disease. It is now widely acknowledged that mesenchymal stem/stromal cells exert their therapeutic effects via their secretome, with the principal vector identified as extracellular vesicles. This review will focus on summarizing the current literature and investigations on mesenchymal stem/stromal cell-derived extracellular vesicles as a treatment for neonatal diseases and examine the considerations to their application in the clinical setting.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Displasia Broncopulmonar
/
Nascimento Prematuro
/
Doenças do Prematuro
Limite:
Female
/
Humans
/
Infant
/
Newborn
/
Pregnancy
Idioma:
En
Revista:
Semin Perinatol
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos